Log in

Zymeworks Price Target, Predictions & Analyst Ratings

+1.31 (+2.70 %)
(As of 11/27/2020 12:00 AM ET)
Today's Range
Now: $49.86
50-Day Range
MA: $43.22
52-Week Range
Now: $49.86
Volume307,810 shs
Average Volume441,166 shs
Market Capitalization$2.29 billion
P/E RatioN/A
Dividend YieldN/A

Analyst Ratings

Zymeworks (NYSE:ZYME) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
11 Wall Street analysts have issued ratings and price targets for Zymeworks in the last 12 months. Their average twelve-month price target is $52.91, predicting that the stock has a possible upside of 6.12%. The high price target for ZYME is $70.00 and the low price target for ZYME is $42.00. There are currently 1 hold rating, 9 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
ZYME Consensus Rating: BuyBuyBuyBuy
ZYME Consensus Rating Score:
ZYME Analyst Ratings: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
10 Buy Rating(s)
1 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
1 Strong Buy Rating(s)
ZYME Consensus Price Target: $52.91$52.91$52.91$50.73
ZYME Price Target Upside: 6.12% upside37.45% upside39.70% upside35.24% upside

Zymeworks (NYSE:ZYME) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Zymeworks (NYSE:ZYME) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2020Raymond JamesSet Price TargetStrong-Buy$60.00High
9/29/2020JPMorgan Chase & Co.Initiated CoverageNeutralLow
8/6/2020SVB LeerinkInitiated CoverageOutperform$45.00Medium
7/14/2020GuggenheimLower Price Target$54.00 ➝ $48.00Low
7/13/2020Canaccord GenuityBoost Price TargetBuy$25.00 ➝ $42.00High
7/9/2020HC WainwrightLower Price TargetBuy$60.00 ➝ $54.00Medium
6/14/2020Bloom BurtonReiterated RatingBuyLow
6/2/2020CitigroupBoost Price TargetBuy$49.00 ➝ $50.00High
5/8/2020Paradigm CapitalReiterated RatingBuy$51.00Medium
2/3/2020Stifel NicolausBoost Price TargetBuy$45.00 ➝ $70.00Medium
1/15/2020Wells Fargo & CompanyReiterated RatingOverweight$48.00 ➝ $58.00Low
1/10/2020Wolfe ResearchInitiated CoverageOutperform$61.00High
8/5/2019BarclaysBoost Price TargetEqual Weight$15.00 ➝ $23.00Medium
7/18/2019Deutsche Bank AktiengesellschaftInitiated CoverageBuy ➝ Buy$34.00Medium
5/14/2018LADENBURG THALM/SH SHInitiated CoverageBuy$25.00Low
(Data available from 11/29/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)
This page was last updated on 11/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.